|
"valle jw"的相關文件
顯示項目 1-17 / 17 (共1頁)
1
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2025-05-15 |
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, R;Avallone, A;Cundom, J;Kuzko, A;Wang, J;Xynos, I;Vogel, A;Valle, JW |
| 國家衛生研究院 |
2025-03 |
Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study
|
Biesma, NC;Graus, MUJE;Cirkel, GA;Besselink, MG;de Groot, JWB;Koerkamp, BG;Herbschleb, KH;Los, M;Verdonk, RC;Wilmink, JW;Cervantes, A;Valle, JW;Valkenburg-van Iersel, LBJ;Froeling, FEM;Molenaar, IQ;Daamen, LA;de Vos-Geelen, J;van Santvoort, HC;Bockorny, B;Carrato, A;Chen, L;Coveler, AL;Dajani, O;Diaz, LA;El-Rayes, BF;Goldstein, D;Halfdanarson, TR;Hosein, PJ;Kim, EJ;Liang, T;Melisi, D;Pruijt, JFM;Santoro, A;Verschoor, AJ;van Voorthuizen, T |
| 國家衛生研究院 |
2024-08 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study
|
Oh, DY;He, AR;Bouattour, M;Okusaka, T;Qin, S;Chen, LT;Kitano, M;Lee, CK;Kim, JW;Chen, MH;Suksombooncharoen, T;Ikeda, M;Lee, MA;Chen, JS;Potemski, P;Burris, HA, 3rd;Ostwal, V;Tanasanvimon, S;Morizane, C;Zaucha, RE;McNamara, MG;Avallone, A;Cundom, JE;Breder, V;Tan, B;Shimizu, S;Tougeron, D;Evesque, L;Petrova, M;Zhen, DB;Gillmore, R;Gupta, VG;Dayyani, F;Park, JO;Buchschacher, GL, Jr.;Rey, F;Kim, H;Wang, J;Morgan, C;Rokutanda, N;Żotkiewicz, M;Vogel, A;Valle, JW |
| 國家衛生研究院 |
2024-06-17 |
Plain language summary of the FOENIX-CCA2 study: Futibatinib for people with advanced bile duct cancer
|
Goyal, L; Meric-Bernstam, F; Hollebecque, A; Valle, JW; Morizane, C; Karasic, TB; Abrams, TA; Furuse, J; Kelley, RK; Cassier, PA; Klümpen, HJ; Chang, HM; Chen, LT; Tabernero, J; Oh, D; Mahipal, A; Moehler, M; Komatsu, Y; Ahn, DH; Epstein, RS; Halim, AB; Wacheck, V; He, YH; Liu, M; Benhadji, KA; Bridgewater, JA |
| 國家衛生研究院 |
2023-09-25 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
|
Oh, DY;He, AR;Qin, SK;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, H;Bouattour, M;Tanasanvimon, S;McNamara, MG;Zaucha, R;Avallone, A;Tan, BJM;Cundom, J;Lee, CK;Takahashi, H;Ikeda, M;Chen, JS;Wang, JL;Makowsky, M;Rokutanda, N;Zotkiewicz, M;Kurland, JF;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2023-03-31 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462
|
Oh, D;He, AR;Qin, S;Chen, L;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasa, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Żotkiewicz, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2023-01-19 |
Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma
|
Goyal, L; Meric-Bernstam, F; Hollebecque, A; Valle, JW; Morizane, C; Karasic, TB; Abrams, TA; Furuse, J; Kelley, RK; Cassier, PA; Klümpen, HJ; Chang, HM; Chen, LT; Tabernero, J; Oh, DY; Mahipal, A; Moehler, M; Mitchell, EP; Komatsu, Y; Masuda, K; Ahn, D; Epstein, RS; Halim, AB; Fu, Y; Salimi, T; Wacheck, V; He, Y; Liu, M; Benhadji, KA; Bridgewater, JA |
| 國家衛生研究院 |
2022-11 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Lee, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Zotkiewicz, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2022-09 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Watras, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2022-06 |
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements
|
Goyal, L;Meric-Bernstam, F;Hollebecque, A;Morizane, C;Valle, JW;Karasic, TB;Abrams, TA;Kelley, RK;Cassier, PA;Furuse, J;Klumpen, HJ;Chang, HM;Chen, LT;Komatsu, Y;Masuda, K;Ahn, DH;Li, K;Benhadji, KA;Wacheck, V;Bridgewater, JA |
| 國家衛生研究院 |
2022-02-01 |
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, R;Avallone, A;Cundom, J;Rokutanda, N;Xiong, J;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2021-10 |
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study
|
Valle, JW;Vogel, A;Denlinger, CS;He, AR;Bai, LY;Orlova, R;Van Cutsem, E;Adeva, J;Chen, LT;Obermannova, R;Ettrich, TJ;Chen, JS;Wasan, H;Girvan, AC;Zhang, W;Liu, JG;Tang, CL;Ebert, PJ;Aggarwal, A;McNeely, SC;Moser, BA;Oliveira, JM;Carlesi, R;Walgren, RA;Oh, DY |
| 國家衛生研究院 |
2021-09 |
Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
|
Mohler, M;Goyal, L;Meric-Bernstam, F;Hollebecque, A;Morizane, C;Valle, JW;Karasic, TB;Abrams, TA;Kelley, RK;Cassier, P;Furuse, J;Klumpen, HJ;Chang, HM;Chen, LT;Komatsu, Y;Masuda, K;Ahn, D;He, Y;Soni, N;Benhadji, KA;Bridgewater, JA |
| 國家衛生研究院 |
2021-07 |
Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
|
Goyal, L;Meric-Bernstam, F;Hollebecque, A;Morizane, C;Valle, JW;Karasic, TB;Abrams, TA;Kelley, RK;Cassier, P;Furuse, J;Klumpen, HJ;Chang, HM;Chen, LT;Komatsu, Y;Masuda, K;Ahn, D;He, YH;Soni, N;Benhadji, KA;Bridgewater, JA |
| 國家衛生研究院 |
2020-02 |
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study
|
Valle, JW;Bai, LY;Orlova, R;Van Cutsem, E;Alfonso, JA;Chen, LT;Obermannova, R;Ettrich, TJ;Chen, JS;Wasan, HS;Denlinger, CS;Vogel, A;He, AR;Bousmans, N;Girvan, AC;Zhang, W;Walgren, RA;Carlesi, R;Oh, DY |
| 國家衛生研究院 |
2019-10 |
A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
|
Oh, DY;Chen, LT;He, AR;Okusaka, T;Qin, S;Chin, S;Rokutanda, N;Uchinda, H;Vogel, A;Valle, JW;Kim, H |
| 國家衛生研究院 |
2019-02 |
A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements
|
Goyal, L;Bahleda, R;Furuse, J;Valle, JW;Moehler, MH;Oh, DY;Chang, HM;Kelley, RK;Javle, MM;Borad, MJ;Chen, LT;Uboha, NV;Klumpen, HJ;O'Dwyer, PJ;Li, DN;Morizane, C;Huang, J;Bridgewater, JA |
顯示項目 1-17 / 17 (共1頁)
1
每頁顯示[10|25|50]項目
|
